Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is pioneering the field of synthetic biology by providing an innovative horizontal platform for cell programming. Specializing in flexible, end-to-end services, the company addresses diverse challenges across multiple sectors including food, agriculture, pharmaceuticals, industrial chemicals, and specialty chemicals. Ginkgo Bioworks is organized into two primary segments: Cell Engineering and Biosecurity, with the latter contributing the majority of the company's revenue through data analytics and related services.
One of Ginkgo Bioworks' recent highlights includes the acquisition of AgBiome's platform assets, significantly enhancing its R&D capabilities in agricultural biotechnology. This move has expanded Ginkgo's proprietary metagenomics database, creating a rich resource for AI model development. Furthermore, the company is actively engaged in partnerships to amplify its technological reach, such as its collaboration with Il Granaio delle Idee to enhance sourdough bakery strains and with GreenLab to produce brazzein, a high-intensity sweetener, on a commercial scale.
Ginkgo Bioworks is also a key player in biosecurity, developing advanced infrastructure and technologies to predict, detect, and respond to biological threats. The company's upcoming Biofab1, a fully integrated lab data center expected to open in mid-2025, is part of its strategic plan to streamline operations and achieve adjusted EBITDA breakeven by the end of 2026.
Additionally, Ginkgo's platform is making significant strides in the AI and data generation space, offering services that help clients leverage high-quality data for more effective R&D. Notably, the company recently hosted its 5th annual Ferment conference, where it showcased new products and technological advancements to a global audience.
Despite facing some financial challenges, including a need to regain compliance with NYSE listing standards due to stock price fluctuations, Ginkgo remains committed to its mission. The company continues to innovate and form strategic partnerships, such as its recent agreement with Sojitz Corporation to penetrate the Japanese market, enhancing its role in the global bioeconomy.
For more information, visit ginkgobioworks.com or follow them on social media platforms like X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), and LinkedIn.
Sensible Biotechnologies has successfully secured a $4.2 million pre-seed funding round aimed at enhancing its cell-based platform for the efficient manufacturing of high-quality mRNA. The funding, led by BlueYard Capital and supported by notable investors such as Y Combinator and Recode Health Ventures, will facilitate the optimization and scalability of the company's mRNA production capabilities. This initiative is vital as current manufacturing methods struggle with quality and scalability issues. The investment follows a strategic partnership with Ginkgo Bioworks (NYSE: DNA), which will help accelerate the development of Sensible's innovative platform. The funding marks a significant step towards unlocking the potential of mRNA technology for therapeutic applications.
Ginkgo Bioworks (NYSE: DNA) announced the acquisition of StrideBio’s adeno-associated virus (AAV) capsid discovery platform, enhancing its gene therapy capabilities. This transaction includes StrideBio's library of optimized capsids and preclinical data for a genetic heart disease asset. Ginkgo aims to leverage these resources to improve targeting and safety in gene therapies, addressing current limitations in the AAV field. The acquisition solidifies Ginkgo's position as a comprehensive service provider in gene therapy, with expectations to further develop and commercialize advanced gene therapies.
On April 4, 2023, Solvay announced a strategic collaboration with Ginkgo Bioworks (NYSE: DNA) to accelerate the development of sustainable biopolymers, bolstering its position in biotechnology. This multi-year agreement includes the acquisition of a Ginkgo lab in Cambridge, Massachusetts, enhancing Solvay's research capabilities. The partnership aims to leverage synthetic biology to produce environmentally-friendly materials and meet the increasing demand for sustainable solutions. Solvay's CEO highlighted this investment as a pivotal milestone for future growth.
Sensible Biotechnologies has announced a partnership with Ginkgo Bioworks (NYSE: DNA) to develop an in vivo microbial mRNA manufacturing platform. This collaboration aims to address the limitations of conventional in vitro transcription methods, which often struggle with scale and quality. The new method is expected to produce mRNA at a scale of over 100,000 liters, improving the quality and length of mRNA, thereby potentially unlocking new therapeutic applications. Both companies emphasize the need for more efficient mRNA production as the market expands.
Ginkgo Bioworks (NYSE: DNA) is scheduled to participate in Cowen's 43rd Annual Health Care Conference on March 6, 2023. CEO Jason Kelly will take part in a fireside chat at 9:10 a.m. ET and a SynBio & AI Driven Drug Discovery panel at 4:40 p.m. ET. This involvement highlights the company's strategy to showcase its leadership in the cell programming and biosecurity sectors. Investors can find more details, including webcast links and replays, on the company's investor relations website.
Ginkgo Bioworks Holdings reported a 52% increase in total revenue for 2022, reaching $478 million, exceeding guidance. The company added 59 new Cell Programs, marking 90% growth. Despite this, fourth-quarter revenue fell 34% to $98 million due to reduced COVID-19 testing services. Biosecurity revenue for 2022 was $334 million, up 66%. However, a loss from operations totaled $(2.2) billion, impacted by high stock-based compensation. Ginkgo forecasts at least $275 million in total revenue for 2023, with a plan to add 100 new Cell Programs and expects Biosecurity revenue of at least $100 million.
Ginkgo Bioworks (NYSE: DNA) will host a presentation and Q&A session on March 1, 2023, at 4:30 p.m. ET. This event will review the company's business performance for Q4 and the full year ending December 31, 2022. Details regarding the presentation and a link to the webcast will be available on Ginkgo's investor relations website. Investors can submit questions via Twitter or email prior to the event. Ginkgo Bioworks focuses on cell programming and biosecurity solutions across various industries including food, pharmaceuticals, and public health.
Zymtronix and Ginkgo Bioworks (NYSE: DNA) announced a partnership on February 16, 2023, to enhance enzymes for Zymtronix's cell-free biomanufacturing platform. This collaboration aims to optimize enzyme production for food, agriculture, cosmetics, and pharmaceuticals. Zymtronix's technology addresses challenges in traditional biocatalysis, enabling precise production across various sectors. Ginkgo will provide comprehensive support in enzyme engineering and production, facilitating the commercialization of sustainable ingredients. Both companies are eager to extend this partnership for a broader range of products.
Ginkgo Bioworks (NYSE: DNA) has partnered with the Rwanda Biomedical Centre (RBC) to initiate a one-year pathogen monitoring program at Kigali International Airport aimed at identifying new SARS-CoV-2 variants. This initiative, announced on February 15, 2023, involves monitoring wastewater samples from incoming flights and anonymous nasal swabs from international travelers, providing essential public health data to inform global mitigation strategies. The program enhances biosecurity and complements existing initiatives at U.S. airports. Ginkgo will supply support in collection, analysis, and bioinformatics, while RBC will manage operational tasks on-site.
Ginkgo Bioworks (NYSE: DNA) and Bioweg have announced a collaboration aimed at creating sustainable alternatives to synthetic polymers, particularly focusing on bacterial cellulose production. This partnership addresses the rising concerns over microplastic pollution, which significantly impacts health and the environment. Bioweg's biodegradable cellulose products are already being utilized as substitutes for synthetic polymers across various industries, aligning with regulatory efforts to mitigate microplastics. Ginkgo's advanced strain engineering capabilities will support Bioweg in optimizing production and achieving competitive pricing, showcasing a commitment to performance and sustainability.
FAQ
What is the current stock price of Ginkgo Bioworks Holdings (DNA)?
What is the market cap of Ginkgo Bioworks Holdings (DNA)?
What does Ginkgo Bioworks do?
What are the main segments of Ginkgo Bioworks?
What recent acquisitions has Ginkgo Bioworks made?
What is Biofab1?
Who are Ginkgo Bioworks' partners?
What is Ginkgo's role in biosecurity?
How is Ginkgo integrating AI in its operations?
What financial challenges is Ginkgo facing?
How can I stay updated with Ginkgo Bioworks' latest news?
When is Ginkgo's next financial update?
